Patient Care and Therapeutic Decision-Making
Domain 1 - Patient Care and Therapeutic Decision-Making
This domain tests whether you can convert a raw patient presentation - symptoms, labs, medication list, social context - into a defensible, prioritized therapeutic plan, and then defend the plan rather than just name a drug. Questions rarely ask "what is first-line for X" in isolation; they ask what you should do next for this patient.
The reasoning sequence the exam rewards
- Frame the problem. Separate acute/urgent issues from chronic ones, and separate drug-related problems (non-adherence, adverse effect, untreated indication, dose too high) from new disease.
- Set explicit goals. Symptom relief, target blood pressure/A1C/LDL, prevention of hospitalization, function and quality of life. Goals determine what counts as success.
- List alternatives - including "no new drug" and "deprescribe."
- Select using patient-specific factors: age, renal and hepatic function, comorbidities, pregnancy and lactation, allergies, interactions, cost and coverage, adherence history, and patient preference.
- Define monitoring - the parameter, the frequency, who does it, and the stop/continue rule.
- Arrange follow-up and document the plan.
Prioritization
Treat the most dangerous, most reversible problem first. If a patient presents with postural hypotension, bradycardia and dizziness on bisoprolol plus verapamil, the antihypertensive regimen - not the newly reported insomnia - is the problem.
Worked example
A 64-year-old with type 2 diabetes (A1C 8.4%), eGFR 62 mL/min/1.73 m², urine albumin-to-creatinine ratio 32 mg/mmol, BP 148/88, no established atherosclerotic disease, taking metformin 1000 mg twice daily. What do you recommend?
- Problem list: uncontrolled A1C; albuminuria with hypertension; cardiovascular risk without established disease.
- Reasoning: metformin is already at a tolerated dose, so add a second glucose-lowering agent chosen partly for comorbidity benefit (an SGLT2 inhibitor or GLP-1 receptor agonist fits albuminuria and cardiovascular risk); block the renin–angiotensin system for albuminuria with an ACE inhibitor or an ARB, never both; consider a statin given age and diabetes.
- Monitoring: eGFR and potassium 1–2 weeks after starting RAS blockade; A1C at 3 months.
Traps that cost marks
- Answering the guideline instead of the patient (recommending a drug the patient cannot afford or access).
- Forgetting renal dose adjustment, or doubling RAS blockade.
- Intensifying therapy before checking adherence and actual medication-taking.
- Recommending a change outside your scope without naming the prescriber conversation you would initiate.